Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review

Table 2

Meta-analysis.

	Study	HR (95% CI)
Region
Asian	31	1.92 (1.71–2.16)	<0.001	21.6%	0.143
Non-Asian	5	2.28 (1.81–2.89)	<0.001	47.4%	0.107
Number of patients
≤100	16	2.27 (1.79–2.88)	<0.001	0%	0.814
>100	20	1.93 (1.71–2.16)	<0.001	47.2%	0.011
Sources of HR
HR	16	2.01 (1.75–2.30)	<0.001	39.2%	0.055
SC	20	1.96 (1.67–2.31)	<0.001	17%	0.242
Quality score
5–8	13	2.27 (1.82–2.83)	<0.001	0%	0.785
9-10	23	1.91 (1.70–2.15)	<0.001	41.7%	0.020
Cancer type
BC	4	2.46 (1.87–3.22)	<0.001	65.1%	0.035
GC	3	2.27 (1.13–4.58)	0.022	0%	0.747
HCC	4	1.90 (1.48–2.44)	<0.001	59.5%	0.060
NSCLC	7	1.82 (1.46–2.28)	<0.001	0%	0.864
PDA	3	1.73 (1.05–2.86)	0.032	47.2%	0.151
OC	3	1.34 (0.96–1.88)	0.084	0%	0.587
Others	12	2.04 (1.72–2.42)	<0.001	27.6%	0.159
Overall	36	2.02 (1.81–2.25)	<0.001	25.6%	0.09